Dr. Reddy's Laboratories Regains Worldwide Rights To DFA-02 - Quick Facts

(RTTNews) - Dr. Reddy's Laboratories Ltd. (RDY), along with its subsidiaries, announced the termination of the license granted to Armis Biopharma, Inc. for its investigational antibacterial product, DFA-02, for the prophylaxis of surgical site infections.

Due to this license termination, Dr. Reddy's has regained worldwide rights to DFA-02, and is currently evaluating its options to take the program forward.

DFA-02 is a combination, broad spectrum antibacterial in situ gel which is being investigated for the prophylaxis of SSIs as an adjunct to conventional preoperative antibiotic prophylaxis. DFA-02 has been studied in several phase 1 and 2 clinical studies, and has showed clinical efficacy in several key segments of patients who were at high risk for SSIs.